AAP Grand Rounds Subscribe to Pediatrics in Review
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 16 No. 4, October 2006
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiedermann, B. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wiedermann, B. L.
Related Collections
Right arrow Weighing the Evidence

AAP Grand Rounds 16:39 (2006)
© 2006 American Academy of Pediatrics

RHEUMATOLOGY

Weighing the Evidence: Can We Believe an Open-Label Study?

Bernhard L. Wiedermann, MD, FAAP
The first 20% of the full text of this article appears below.

For treatment studies, blinding of intervention is considered optimal to avoid bias in assessing outcomes. Ideally, both the patient (and his/her family) and the caregivers (including anyone responsible for assessing outcomes) are blinded; this is termed a double-blind study. However, sometimes this is difficult or even impossible. Studies involving a surgical vs medical intervention could not be blinded easily for . . . [Full Text of this Article]






HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Academy of Pediatrics.